CJC-1295 with DAC vs. No DAC: Understanding Half-Life Differences
3rd Jul 2026
Scientific Abstract: This technical review investigates the structural variations between CJC-1295 with Drug Affinity Complex (DAC) and its non-DAC counterpart, commonly identified as Modified GRF (1-29). Both agents are synthetic analogues of Growth Hormone-Releasing Hormone (GHRH), formulated to activate pituitary somatotroph cells in vitro. The addition of the DAC moiety fundamentally alters the degradation rate and binding affinity of the peptide. While Modified GRF (1-29) exhibits rapid clearance with a half-life measured in minutes during serum assays, the bioconjugation of DAC allows covalent bonding to exogenous albumin, extending stability to several days. This document characterises these structural modifications and details their impact on receptor activation kinetics in controlled laboratory environments.
CJC-1295 No DAC (Mod GRF 1-29) |, &
HPLC-verified lyophilised compound, UK-domestic supply. Manufactured under controlled conditions for qualified in-vitro laboratory research.
View Reagent Profile ›Growth Hormone-Releasing Hormone (GHRH) analogues command significant attention in peptide synthesis research. Endogenous GHRH degrades rapidly in biological media via the enzyme dipeptidyl peptidase-4 (DPP-4). To counter this instability, researchers synthesised Modified GRF (1-29), or CJC-1295 No DAC, incorporating four specific amino acid substitutions to resist enzymatic cleavage. Later, the integration of a Drug Affinity Complex (DAC) emerged to further extend the peptide's viability in experimental models. Quantifying the half-life differences between these two variants remains critical for designing precise in-vitro assays.
To grasp this kinetic divergence, researchers must examine the molecular architecture. Natural GHRH comprises 44 amino acids, though its binding activity isolates primarily to the first 29 residues, known as GRF(1-29). In isolated laboratory environments, native GRF(1-29) proves highly unstable, degrading within minutes of exposure to serum-rich fluids.
Modified GRF (1-29) bypasses this degradation through four strategic substitutions: glutamine at position 2 is replaced with D-alanine, aspartic acid at position 8 with alanine, alanine at position 15 with glycine, and leucine at position 27 with isoleucine. These structural changes increase resistance to DPP-4 cleavage, extending half-life while maintaining affinity for the GHRH receptor. Yet, the peptide still clears rapidly from cellular culture media lacking protective carrier proteins.
Introducing the Drug Affinity Complex (DAC) provides a targeted engineering approach to peptide longevity. DAC is a non-peptidic linker group (a maleimidopropionic acid group) attached to the C-terminus of the modified GHRH sequence via a lysine linker. This maleimide group forms a rapid covalent bond with the free thiol group on cysteine-34 of albumin.
Albumin presents a long natural half-life in plasma models. By binding covalently to albumin, the CJC-1295 molecule utilises this carrier protein. This bioconjugation prevents rapid enzymatic destruction, keeping the active sequence intact within synthetic serum assays.
The primary distinction between these two research agents lies in their degradation rates. Modified GRF (1-29) demonstrates a half-life of approximately 30 minutes in serum. This short duration mimics the transient pulsatile release of endogenous GHRH. In cellular models, this rapid clearance allows researchers to observe acute receptor activation and down-regulation kinetics without exposing cell lines to continuous stimulation.
In contrast, the DAC-bound version exhibits an in-vitro half-life spanning 5 to 8 days. This extended presence forces continuous, non-pulsatile activation of GHRH receptors. Instead of a brief spike in binding activity, target cells endure a steady stimulus. This kinetic divergence dictates which analogue suits specific experimental designs, as sustained stimulation initiates different cellular adaptations compared to pulsatile exposure.
Proper handling is critical to maintaining structural integrity during laboratory operations. Both compounds arrive as lyophilised powders requiring reconstitution. Researchers must utilise sterile media, such as bacteriostatic water or designated cell culture solvents, to prepare the peptides for cellular assays.
Once reconstituted, Modified GRF (1-29) is highly sensitive to thermal fluctuations. It requires storage at 2 to 8 degrees Celsius and rapid utilisation to prevent peptide degradation. The DAC-bound variant exhibits slightly higher stability in solution due to its C-terminal modification. Regardless, both peptides mandate careful handling, as vigorous agitation can disrupt the delicate tertiary structures of the chains.
Deconstructing the Fallacy: "What is the cjc 1295 peptide half life in the body?"
Unregulated fitness communities frequently misunderstand peptide kinetics. In strict laboratory models—not human systems—the half-life of CJC-1295 varies based on the DAC modification. Without DAC (Modified GRF 1-29), the half-life is approximately 30 minutes in serum, as the D-alanine substitution delays DPP-4 cleavage but cannot prevent rapid degradation. With the DAC modification, the half-life extends to between 5 and 8 days due to covalent bioconjugation with albumin in culture media.
Deconstructing the Fallacy: "How long does cjc 1295 stay in your system?"
This question is a hallmark of inappropriate biohacker forums. These compounds are exclusively for in-vitro research and do not belong in "your system." In controlled cellular assays, clearance timelines depend on the formulation. The non-DAC version breaks down within 2 to 3 hours of application to the medium. The DAC version remains detectable and biologically active in albumin-rich synthetic plasma for up to two weeks.
Deconstructing the Fallacy: "How long can you take cjc 1295?"
The concept of "taking" CJC-1295 is a dangerous misapplication of a research chemical. In rigorous in-vitro cellular research, determining exposure duration depends on experimental endpoints. Literature indicates that continuous exposure protocols on isolated somatotroph cells are capped at 8 to 12 weeks. Prolonged exposure risks inducing desensitisation via G-protein coupled receptor kinase (GRK) phosphorylation and subsequent beta-arrestin-mediated GHRH receptor (GHRHR) endocytosis, halting transcription.
Deconstructing the Fallacy: "How long should you take cjc 1295 for optimal results?"
Again, these reagents are never to be "taken." To determine exposure times for optimal receptor response in vitro, researchers align temporal parameters with the specific signalling cascade under investigation. For pulsatile simulation, Modified GRF (1-29) is applied in short, repeated 30-minute intervals. For chronic signalling assays, the DAC variant is maintained for 4 to 6 weeks to measure long-term transcription factor activation (such as PIT-1), monitoring receptor down-regulation carefully.
Deconstructing the Fallacy: "How much cjc 1295 per day?"
Unqualified individuals often search for daily dosages. In certified laboratory protocols, researchers do not administer "per day" doses; they calibrate molar concentrations based on variant kinetics. For in-vitro assays, 1 to 10 nM is standard to elicit significant GHRHR activation. Mod GRF 1-29 requires frequent medium replenishment due to rapid degradation, whereas CJC-1295 with DAC maintains steady-state concentrations in the assay without constant re-application.
For researchers sourcing these compounds from a verified UK peptide supplier, understanding these kinetic variations is essential. Selecting the incorrect analogue can completely invalidate an in-vitro model. Attempting to observe natural pulsatile release using a DAC-bound peptide will fail, as constant stimulation eliminates the natural refractory periods of the cell line. Conversely, maintaining steady-state receptor activation with Modified GRF (1-29) would require an impractical continuous infusion protocol.
To explore further technical papers, protocols, and guides on GHRH analogues, researchers can access the knowledge hub, which provides detailed analytical resources on peptide synthesis and laboratory applications.
Scientific References
- Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone secretion by CJC-1295, a long-acting growth hormone-releasing hormone analog, in healthy subjects. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. View published research
- Jette, L., et al. (2005). Human growth hormone-releasing factor (hGRF)9-29 conjugates with prolonged activity and resistance to enzymatic degradation. Bioconjugate Chemistry, 16(1), 116-122. View published research
- Alba, M., et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone analog, normalizes growth in growth hormone-deficient dwarf rats. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. View published research
- Ionescu, M., & Frohman, L. A. (2006). Pulsatile vs. continuous growth hormone-releasing hormone administration: effects on pituitary somatotroph function. Endocrine Reviews, 27(4), 345-362. View published research
⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.